Evidence map›Paper›PMID 36346544›Full record

Trial reportInternational journal of clinical pharmacy2023

Clinical effects of remimazolam alone or in combination with dexmedetomidine in patients receiving bronchoscopy and influences on postoperative cognitive function: a randomized-controlled trial.

Shenqiang Gao, Tingting Wang, Li Cao, Linyan Li, Shengqiang Yang

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 9 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 9 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shenqiang GaoDepartment of Anesthesiology, Taian City Central Hospital, Taishan District, No.29, Longtan Road, Taian, 271000, Shandong Province, China.
Tingting WangDepartment of Anesthesiology, Taian City Central Hospital, Taishan District, No.29, Longtan Road, Taian, 271000, Shandong Province, China.
Li CaoDepartment of Anesthesiology, Taian City Central Hospital, Taishan District, No.29, Longtan Road, Taian, 271000, Shandong Province, China.
Linyan LiDepartment of Anesthesiology, Shandong First Medical University, Taian, 271016, Shandong Province, China.
Shengqiang YangDepartment of Anesthesiology, Taian City Central Hospital, Taishan District, No.29, Longtan Road, Taian, 271000, Shandong Province, China. ysq808080@163.com.ORCID http://orcid.org/0000-0002-5468-7835
Taian City Central Hospital · CNTaishan Medical University · CN

Funding

Scientific Research Foundation of comfort medicine of Shandong Province Medical Association in 2020 YXH2020ZX023
6 · The paper itself

Abstract

backgroundRemimazolam and dexmedetomidine are commonly used as sedatives. However, the effects and safety of remimazolam alone or in combination with dexmedetomidine have not been investigated.

aimWe sought to investigate the clinical effects of remimazolam alone or in combination with dexmedetomidine in bronchoscopy, and their influence on cognitive function.

methodNinety eligible patients who underwent bronchoscopy under intravenous anesthesia were randomly divided into three groups: propofol control, remimazolam, and remimazolam plus dexmedetomidine. The primary outcome was the incidence of perioperative hypoxemia. Secondary outcomes included induction and maintenance doses of remimazolam, hemodynamic variables, scores for modified Observer's Assessment of Alertness/Sedation (MOAA/S), coughing, limb movement, incidence of adverse events, patient satisfaction, bronchoscopist satisfaction, incidence of post-operative cognitive dysfunction (POCD), time to loss of consciousness (LoC), and time to awake.

resultsThe incidence of hypoxemia, hypotension, and bronchoscopist satisfaction score were significantly decreased, and time to LoC and time to awake were markedly longer in the remimazolam and remimazolam plus dexmedetomidine groups than in the propofol control group (p < 0.05). The remimazolam group had significantly decreased induction and maintenance doses of remimazolam and a shorter time to LoC than the remimazolam plus dexmedetomidine group (p < 0.05). Scores for coughing, limb movement, MOAA/S, and post-operative patient satisfaction were comparable among the three groups. POCD was not induced in any of the groups.

conclusionRemimazolam is safe and effective for painless bronchoscopy, with a low incidence of adverse reactions, and exhibits a good synergistic effect with dexmedetomidine.

trial registrationThis trial protocol had been registered on Chinese Clinical Trial Registry (ChiCTR2000041435, date: 2020 12 26.

Indexed as

DexmedetomidinePropofolBenzodiazepinesBronchoscopyCognitionHumansHypnotics and SedativesHypoxiaBenzodiazepinesDexmedetomidineHypnotics and SedativesPropofolremimazolamBronchoscopyDexmedetomidinePostoperative cognitive dysfunctionPropofolRemimazolam

Identifiers

PMID36346544
OpenAlexW4308553305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.